Dofetilide

454 interactions 653 cited references

Also sold as: Tikosyn Tikosyn®

About Dofetilide

Dofetilide is an antiarrhythmic medication used to treat irregular heartbeats like atrial fibrillation or atrial flutter. Read the full Dofetilide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Sulfamethoxazole Cisapride Bictegravir Cimetidine Sparfloxacin Saquinavir

33 Contraindicated 288 Major 131 Moderate 2 Minor

All (454) Contraindicated (33) Major (288) Moderate (131) Minor (2)

Major

Dofetilide Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dofetilide Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Dofetilide Bretylium An increased risk of cardiotoxicity (QT interval prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dofetilide Ceritinib Zykadia An increased risk of QT interval prolongation Details Dofetilide Chloral Hydrate Cardiotoxicity (QT interval prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Chlorpromazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Ciprofloxacin An increased risk of QT interval prolongation and torsade de pointes Details Dofetilide Citalopram Celexa An increased risk of QT interval prolongation Details Dofetilide Clarithromycin Biaxin Increased dofetilide exposure, increased risk of QT interval prolongation and torsade de pointes Details Dofetilide Clofazimine An increased risk of QT interval prolongation Details Dofetilide Clomipramine Anafranil An increased risk of QT interval prolongation Details Dofetilide Clothiapine Increased risk of cardiac arrhythmias Details Dofetilide Clozapine Clozaril Increased risk of QT interval prolongation Details Dofetilide Conivaptan Vaprisol Increased CYP3A substrate exposure Details Dofetilide Crizotinib Xalkori Increased dofetilide exposure and an increased risk of QT interval prolongation Details Dofetilide Cyclobenzaprine Amrix An increased risk of QT interval prolongation Details Dofetilide Dabrafenib Tafinlar Reduced CYP3A4 substrate exposure and an increased risk of QT interval prolongation Details Dofetilide Daridorexant Increased CYP3A4 substrate with NTI exposure Details Dofetilide Degarelix Firmagon Increased risk of QT interval prolongation Details Dofetilide Delamanid Increased risk of QT interval prolongation Details Dofetilide Desflurane Suprane An increased risk of QT interval prolongation Details Dofetilide Desipramine Norpramin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Dexmedetomidine Dexased Increased risk of cardiac arrhythmias Details Dofetilide Dibenzepin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Dolasetron Anzemet Cardiotoxicity (QT prolongation, torsade de pointes, cardiac arrest) Details Dofetilide Domperidone Increased risk of QT interval prolongation Details Dofetilide Donepezil Adlarity Increased risk of QT-interval prolongation and torsade de pointes Details Dofetilide Dordaviprone An increased risk of QT interval prolongation Details Dofetilide Doxepin Prudoxin An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Droperidol An increased risk of QT interval prolongation Details Dofetilide Ebastine An increased risk of QT interval prolongation Details Dofetilide Efavirenz An increased risk of QT interval prolongation Details Dofetilide Eliglustat Cerdelga Increased risk of cardiac arrhythmias Details Dofetilide Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Dofetilide Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dofetilide Encorafenib Braftovi Increased risk of QT interval prolongation Details Dofetilide Enflurane An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Dofetilide Entrectinib Rozlytrek An increased risk of QT interval prolongation Details Dofetilide Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.